2003 Cardiovascular Biomarkers and Surrogate Endpoints Symposium

Bethesda, Maryland
August 1-2, 2003

2003 Overview

2003 Agenda

2003 Faculty

As a service to our meeting attendees, the following presentation materials are available for viewing. Please note that material availability is at the discretion of our participating faculty.

If you've installed Windows SP 2, please allow your browser to show active content to view these files.

*Login Required to View Materials - Symposium Registrants will receive a username and password at the time of registration

1. Historical Perspective - Dr. Therese Heinonen
2. Need for Biomarkers in Drug Development - Dr. Donald Black
3. Basic Mechanisms to Biomarkers - Dr. Peter Libby
4. Genetics of CAD - Dr. Daniel Gaudet
5. Impact of Genomics on CAD Breakthroughs - Dr. Jamie Engert
6. Angiography - Dr. David Waters
7. Carotid IMT - Dr. Daniel O'Leary
8. Intravascular Ultrasound - Dr. Jean-Claude Tardif
9. Electron Beam CT Coronary Calcium as a Surrogate - Dr. Pamela Ouyang
10. The Case for Imaging Endpoints in Drug Approval - Dr. Steven Nissen
    (Please contact Dr. Nissen directly at nissens@ccf.org for slide requests)
    
11. A Regulatory Perspective - Dr. David Orloff
12. An NIH Perspective - Dr. Elizabeth Nabel
13. Overview of Lipids and Lipoproteins - Dr. David Waters
14. New Targets and Populations at Risk - Dr. Donald Black
15. Apolipoprotein-Defined Lipoproteins - Dr. Petar Alaupovic
16. Lipoprotein Particle Subclasses - Dr. James Otvos
17. Oxidative Stress 1 - Dr. Jean-Claude Tardif
18. Oxidative Stress 2 - Dr. Sam Tsimikas
19. Endothelial Function - Dr. John Deanfield
20. Cardiac PET - Dr. Marcelo Di Carli
21. Novel Technologies - Dr. Peter Libby
22. Vascular MR and Spiral CT - Dr. Zahi Fayad